Notable transmitted HIV drug resistance among people who

inject drugs in Pakistan

- Stephanie Melnychuk^{1,2}, Laura H. Thompson³, Chris Archibald³, James F. Blanchard¹, Faran 4
- 5 Emmanuel¹, Tahira Reza⁴, Nosheen Dar⁵, Paul Sandstrom², Souradet Y. Shaw¹, Marissa L.
- 6 Becker¹, François Cholette^{2,6}*

1

2

3

7

- 8 ¹Institute for Global Public Health, Department of Community Health Sciences, University of
- 9 Manitoba, Winnipeg, Canada
- 10 ²National Sexually Transmitted and Blood Borne Infection Laboratory, National Microbiology
- 11 Laboratory at the J.C. Wilt Infectious Diseases Research Centre, Public Health Agency of
- 12 Canada, Winnipeg, Canada
- 13 ³Sexually Transmitted and Bloodborne Infections Surveillance Division, Centre for
- 14 Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa,
- 15 Ontario, Canada
- 16 ⁴Centre for Global Public Health, Pakistan, Chak Shahzad, Islamabad, Pakistan
- 17 ⁵Canada-Pakistan HIV/AIDS Surveillance Project, Islamabad, Pakistan
- 18 ⁶Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine,
- 19 University of Manitoba, Winnipeg, Canada.
- 21 *Corresponding author:

20

22 Email: francois.cholette@phac-aspc.gc.ca (FC)

Abstract

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

Transmission of drug-resistant HIV strains to treatment-naïve patients can compromise antiretroviral therapy (ART) effectiveness and lead to treatment failure. In Pakistan, transmitted HIV drug resistance among people who inject drugs (PWID) is fuelled by a lack of ART, poor drug adherence, and unsafe injection practices, resulting in efficient transmission in large injecting networks. A cross-sectional study was conducted among PWID recruited in the Pakistani cities of Karachi, Larkana, Peshawar, Quetta and Hyderabad (August 2014 to January 2015). A portion of the HIV pol gene was amplified from HIV-reactive dried blood spot specimens (n=282/367) and sequenced using an in-house Sanger sequencing assay for HIV drug resistance mutation genotyping. Drug resistance mutations (DRMs) were identified using the Stanford University HIV Drug Resistance Database HIVdb algorithm (https://hivdb.stanford.edu/hivdb). Overall, HIV subtype A1 was dominant (78.0%; n=220), followed by CRF02 AG (15.6%; n=44), CRF35 AD (2.5% n=7), recombinants (3.5%; n=10), and subtype C (0.4% n=1). DRM analysis identified over half (63.8%) of participants harbored at least one DRM, of which 28.9% reported using help from a professional injector. Nearly all (99.4%) participants were not actively receiving ART because most (88.7%) had never undergone HIV testing and were unaware of their status. Findings suggest significant transmitted HIV drug resistance present among PWID, exacerbated by unsafe injection practices, particularly professional injection. Low testing rates signal a need for more comprehensive testing programs to improve HIV status awareness and ART coverage in Pakistan. Given most treatment-naïve participants had evidence of drug resistance, drug resistance genotyping prior to ART initiation might aid in ensuring effective treatment to prevent transmission of resistant HIV strains.

Introduction

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

In Pakistan, HIV prevalence is estimated to be 0.1% in the general population, but is known to be much higher among people who inject drugs (PWID), with estimates as high as 40% of PWID in the country living with HIV (1,2). This considerable burden is attributable to the marginalization of PWID due to contextual factors, including illiteracy, poverty, homelessness, and criminalization (3–5), which constrain access to both harm reduction programs and antiretroviral therapy (ART) (6). Further, the requirement of individuals actively injecting drugs to undergo a two-week drug detoxification prior to ART initiation (7) and lack of a national opioid substitution therapy program in Pakistan presents structural barriers which might contribute to higher rates of HIV transmission among PWID overall, hindering effective HIV management and posing challenges to overall HIV epidemic control efforts in the country (8-10).PWID undergoing ART have increased vulnerability to treatment interruptions due to a lack of social support and stable housing, mental health comorbidities, and effects of stigma and discrimination (9,11,12). Suboptimal therapy and non-adherence to ART facilitates the selection of viral strains harboring drug resistance mutations (DRMs) (13) which can be transmitted to ART-naïve individuals, constituting what is defined as transmitted drug resistance (14). Transmitted drug resistance poses challenges to virological suppression and achieving undetectable viral loads in ART-naïve patients harboring DRMS (15,16), with studies documenting high risk of failing first-line therapy in ART-naïve patients harboring DRMs (17– 19). The disproportionate burden of transmitted drug resistance facing PWID may be fuelled by the rapid and efficient transmission of drug-resistant HIV strains in large, interconnected

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

injecting networks with high frequency of sharing injecting equipment (20,21) in certain contexts, including Pakistan (22). High daily injection frequency (23), sharing syringes and other drug use paraphernalia (22), injection of shared blood-drug mixtures (24), and help from professional injectors (3), have been previously identified as risk factors among PWID in Pakistan. Few studies have looked at baseline HIV DRMs among people living with HIV in Pakistan (5,25–27), with even fewer looking specifically at PWID. Knowledge of DRMs is essential for guiding ART selection, as ARTs are currently prescribed in Pakistan without baseline drug resistance genotyping (26). This increases the risk of ineffective treatment. Using data from a cross-sectional survey conducted in 2014 (28), we sought to assess HIV drug resistance in PWID across five major cities in Pakistan. **Material and Methods Study setting** For this cross-sectional study, PWID were recruited from August 2014 to January 2015 across five major cities in Pakistan. To ensure accurate reflection the study population, a detailed mapping of size, geography, and operation typology of the PWID population was conducted prior to the survey as described previously elsewhere (29). Following informed consent, participants were interviewed to collect information pertaining to sociodemographics, drug use practices, and utilization of HIV prevention and care services, as well as a dried blood spot (DBS) specimen. HIV serology and pol sequencing

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

DBS were shipped to the National Sexually Transmitted and Blood Borne Infection Laboratory (Public Health Agency of Canada, Winnipeg, Canada). Serological testing using the AVIOO HIV Microelisa System (Aviog Inc., Durham, NC) was performed according to the manufacturer's instructions. HIV drug resistance mutation genotyping was attempted on all HIVreactive DBS. A routine, in-house HIV drug resistance mutation genotyping assay was used to amplify and sequence a portion of the pol open reading frame (nt 2,074–3,334 on HXB2, K03455) from DBS as previously described (28). Sequence analysis and contig assembly was performed using RECall (30). HIV pol sequences are available via a public repository (i.e. NCBI) under accession numbers MN887780-MN888069. HIV subtyping and drug resistance mutation analysis PWID HIV pol sequences were aligned, visually inspected, and manually edited in MEGA v7 (31) as required. Subtyping was carried out using REGA HIV automated subtyping tool v3 (32) and COMET (33), with SCUEAL (34) used as a tiebreaker for discordant results. The Stanford HIV Drug Resistance Database program v9.4.1 (https://hivdb.stanford.edu) (35) was used to assess for mutations in the HIV pol gene associated with resistance to protease and reverse transcriptase inhibitors. Sequences containing one or more DRMs were considered drug-resistant (DR). Any DRMs identified for which no clinical implications were found in the literature were discarded. **Statistical analyses** Descriptive statistics were calculated for sociodemographic and behavioral information. Pearson's chi-square test was applied between DR classification and predictor variables using SciPy (36), where P<0.050 was used to define statistically significant associations.

Ethics

Ethics board approval was obtained from the Health Research Ethics Board at the University of Manitoba [HS15691(H2012:294)] and BRIDGE Consultants Foundation, Pakistan. Informed consent was obtained verbally from study participants and documented by a member of the data collection team for the behavioural survey and biological sampling components of this study. Verbal consent was chosen due to varying levels of literacy among study participants and as an additional measure of protecting their identities.

Results

Study population and sequence dataset

Larkana (n = 300), Peshawar (n = 253), Quetta (n = 300) and Hyderabad (n = 300). All participants consented to providing a DBS sample. Serological testing identified 367 (25.5%) PWID living with HIV.

Of the HIV-reactive DBS specimens, 287 pol sequences (79.0%) were amplified – corresponding to 80% of HIV-reactive DBS from each city except Hyderabad, where amplification success was closer to 70%. In accordance with WHO HIV drug resistance criteria (37), five sequences containing premature stop codons were removed from subsequent analysis. Of 282 pol sequences, 109 (38.7%) were from Karachi, 90 (31.9%) from Peshawar, 39 (13.8%) from Hyderabad, 25 (8.9%) from Larkana, and 19 (6.7%) from Quetta. Most sequences were classified as subtype A1 (n=220, 78.0%), followed by CRF02_AG (n=44, 15.6%), CRF35_AD (n=7, 2.5%), recombinants (n=10, 3.5%), and subtype C (n=1, 0.4%).

A total of 1,453 PWID consented to participate in the study from Karachi (n = 300),

Sociodemographic characteristics

Sociodemographic and behavioral information of PWID for whom HIV sequences were obtained is presented in Table 1. All participants were male. Of 282 sequences analyzed, 180 (63.8%) were considered DR.

Statistically significant predictors of DR classification were city of residence and age (P<0.05) (Table 1). Years injecting, daily injection frequency, injection method, and ART status were not significantly associated with DR. Prevalence of DR ranged from 33.3% to 94.7% among participants when stratified by city. Of those with DR sequences, the highest proportion (39.4%) were between 25-29 years of age. Using help from a professional injector was slightly higher in DR participants (28.9%). Of participants who had undergone HIV testing and were aware of their positive status (n=32, 11.3%), one (3.1%) was actively receiving ART.

Table 1. Sociodemographic and behavioral characteristics of people who inject drugs in Pakistan stratified according to presence of drug resistance mutations in HIV sequences.

Variable	DR (≥1 DRM) (<i>N</i> =180)	Non-DR (<i>N</i> =102)	P*
City, n			< 0.001
Hyderabad	35	4	
Karachi	75	34	
Larkana	22	3	
Peshawar	30	60	
Quetta	18	1	
Age, n (%)			0.010
<24	43 (23.9)	40 (39.2)	
25-29	71 (39.4)	26 (25.5)	
≧30	66 (36.7)	36 (35.3)	
Years injecting drugs, n (%) ^a			0.200
<2	32 (17.8)	21 (20.6)	

2-4	64 (35.6)	44 (43.1)	
≧5	84 (46.7)	36 (35.3)	
Times injecting the previous day, <i>n</i> (%)			0.130
0	45 (25.0)	15 (14.7)	
1	74 (41.1)	48 (47.1)	
≧2	61 (31.7)	39 (37.3)	
Injection method at last injection, n (%)			0.200
Without help	104 (57.8)	70 (68.6)	
Uses help, but not from a professional injector	24 (13.3)	10 (9.8)	
Uses help from a professional injector	52 (28.9)	22 (21.6)	
Current ART treatment status, <i>n</i> (%)			0.720
No	19 (10.6)	12 (11.8)	
Yes	1 (0.6)	0 (0.0)	
Not specified ^b	160 (88.9)	90 (88.2)	

Table 1 legend:

155

156

157

158

159

160

161

162

^bLow response rate for HIV treatment is because most participants had never undergone HIV testing and did not respond to questions regarding ART.

Analysis of HIV drug resistance analysis

HIV mutations associated with drug resistance are summarized in Table 2. Of 282 analysed HIV *pol* sequences, 13 DRMs were identified among the 180 DR participants: two protease inhibitor (PI), two nucleoside RT inhibitor (NRTI), and nine non-nucleoside RT inhibitor (NNRTI) mutations (Table 2).

^{**}P-value based on Pearson chi-square test.

^aAmong respondents does not add to 100%.

Table 2. Drug-resistance mutations in HIV sequences from people who inject drugs across

several Pakistani cities.

163

164

		All cities (N=282)	Hyderabad (N=39)	Karachi (N=109)	Larkana (N=25)	Peshawar (N=90)	Quetta (N=19)
DRMs ^a , n (%)							
PIS	M46I*	1 (0.4)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
	L10F	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)
NRTIs	K219R*	(0.7)	0 (0.0)	2 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
	S68G	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)
	K101E*	(0.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 2.2)	0 (0.0)
	K103N*	3 (1.1)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.2)	(5.3)
	V106I	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)
NNRTIS	E138A	164 (58.2)	34 (87.2)	70 (64.2)	22 (88.0)	21 (23.3)	17 (89.5)
	E138APQ	1 (0.4)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
	V179D	(0.7)	0 (0.0)	0 (0.0)	1 (4.0)	0 (0.0)	1 (5.3)
	V179T	(3.9)	1 (2.6)	5 (4.6)	0 (0.0)	4 (4.4)	1 (5.3)
	V179IT	(0.7)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	1 (5.3)
	Y188H*	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.3)
Geno	otype, <i>n</i> (%)						
A	1	220 (78.0)	35 (89.7)	73 (67.0)	22 (88.0)	73 (81.1)	17 (89.5)
C	CRF 02_AG	44 (15.6)	1 (2.6)	29 (26.6)	3 (12.0)	10 (11.1)	1 (5.3)
F	REC ^b	10 (3.5)	2 (5.1)	1 (0.9)	0 (0.0)	7 (7.8)	0 (0.0)
C	CRF 35_AD	7 (2.5)	1 (2.6)	5 (4.6)	0 (0.0)	0 (0.0)	1 (5.3)
(2 legend:	(0.4)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)

Table 2 legend:

*DRM belongs to WHO 2009 list of mutations for surveillance of HIV drug resistance (38). ^aPIs: M46I is associated with low- to intermediate-level resistance to indinavir, nelfinavir, fosamprenavir, lopinavir, saquinavir, and atazanavir (39); and L10F is an accessory DRM associated with reduced lopinavir and darunavir susceptibility (40). NRTIs: K219R confers resistance to azidothymidine (41,42); and S68G is associated with K65R mutants to improve viral replication (43). NNRTIs: K101E confers highly-reduced susceptibility to nevirapine and decreases efavirenz, etravirine, and rilpivirine susceptibility (44); K103N is associated with resistance to nevirapine and efavirenz (45,46); V106I confers potential low-level resistance to doravirine, etravirine, nevirapine, and rilpivirine (47): E138A and E138Q confer reduced susceptibility to etravirine and reduced, potentially full, susceptibility to rilpivirine (48,49); V179D is associated with low-level resistance to efavirenz, nevirapine, etravirine, and rilpivirine (50); V179T has been reported with reduced susceptibility to etravirine in the presence of other DRMs (51); V179I is associated with resistance to etravirine and rilpivirine (52); and Y188H has been reported to confer resistance to nevirapine and efavirenz (53). b"REC" indicates sequences classified as recombinants. DRM E138A was the most common mutation across all cities (58.2%), with almost all sequences from Hyderabad, Larkana, and Quetta containing this mutation (87.2%, 88.0%, and 89.5%, respectively). Karachi sequences had the only reports of DRMs M46I, K219R, and V179T. Despite Peshawar having the smallest percentage (33.3%) of sequences containing any DRMs, these sequences had the most diversity, containing 7 of the 13 DRMs in our analysis, including the only observances of L10F, S68G, K101E, and V106I. The mutation K103N was only reported in two sequences from Peshawar and one sequence from Quetta.

Discussion

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

Here, we present HIV drug resistance mutations from a cross-sectional survey conducted in 2014 among PWID from five cities in Pakistan. Our analysis demonstrated a high prevalence of DRMs associated with NNRTI resistance. The vast majority of participant sequences from Hyderabad (89.7%), Karachi (68.8%), Larkana (88.0%), and Quetta (94.7%) contained at least one DRM. Given that only one (0.6%) study participant reported actively receiving ART, observing DRMs in high frequency among participants suggests significant HIV transmitted drug resistance present among PWID in Pakistan. Over half (58.2%) of PWID in our study harbored E138A, conferring low-level resistance to the NNRTIs etravirine and rilpivirine (48,49). Other studies have observed E138A among people living with HIV in Pakistan, reporting varying prevalence in ART-experienced (13-78%) and ART-naïve (8-39%) cohorts (5.27). Perhaps more concerning are the DRMs observed in low prevalence conferring resistance to efavirenz– namely K101E (44), K103N (45,46), V179D (50), and V188H (53). Pakistan's first-line ART regimen for adults is currently tenofovir and lamivudine with dolutegravir (54), although efavirenz was formerly used in first-line regimes at the time of our study (55) and is currently suggested for use in alternate regimes. Our results suggest first-line regimes would be effective treatment for most PWID living with HIV who participated in our study, although this might not be true for previous regimes. While Pakistan has second-line regimens, these drugs are more prone to shortages compared with first-line regimes (56), posing challenges to HIV treatment in individuals harboring resistance to efavirenz prior to the change to dolutegravir in 2019 (57) and enabling transmission of drug-resistant strains. We observed city of residence and age to be significantly associated with DR classification. Participants with DR sequences reported slightly higher prevalence of help from a

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

professional injector compared to non-DR sequences (28.9% versus 21.6% respectively), and while method at last injection was not significantly associated to DR, we did not stratify the analysis by city and injection method to determine its significance for each study city. Professional injectors (or street doctor) are PWID themselves who reuse the same injecting equipment to inject several clients – often younger and inexperienced PWID – daily, for a fee (58–60). This fee can be something known as "scale", a blood-drug mixture collected by the professional injector by double-pumping the syringe, which is then sold to other PWID for less than the regular drug (22,28,61), allowing for efficient transmission of drug-resistant HIV. Using help from professional injectors has previously been reported to be more prevalent in Karachi (53.7%) compared to Peshawar (25.2%) and Quetta (19.6%) (59). Differences in DRM prevalence among cities might also be partially explained by varying rates of heroin injection, observed to be high in Karachi and Quetta (96.9% and 81.1% respectively) (59). Heroin has been associated with high-risk injection practices, such as needle sharing and "jerking", where heroin is mixed with blood and shared amongst injectors (6), facilitating transmission of resistant strains among PWID. In this study, we report the spread of drug-resistant HIV is likely being fuelled by the lack of ART coverage among PWID participants, permitting high viral loads which enable efficient HIV transmission. Our findings stress the lack of ART coverage among PWID in Pakistan, known to still be an ongoing issue and major obstacle to HIV treatment in the country. The low ART coverage observed in our study is likely due in part to the lack of participants' awareness that they are living with HIV overall, as we observed nearly all (88.7%) PWID participants to have never undergone HIV testing. Awareness of HIV status among people in Pakistan is known to be low (21%), with people living with HIV actively receiving ART being

even lower (12%) (62). Moreover, it is well established that PWID face barriers to ART access, specifically identifying Pakistan's lack of national opioid substitution therapy program as a key intervention to HIV prevention that remains illegal (8,11).

Conclusions

By sequencing, genotyping, and assessing for HIV drug resistance, we have been able to identify the circulating HIV strains and the level of drug resistance among PWID in Pakistan. Overall, our study indicates that few DRMs are found amongst PWID in Pakistan conferring low-level resistance to etravirine, rilpivirine, and efavirenz. While our results suggest the majority of PWID in our study would be susceptible to current first-line ART regimes, perhaps more concerning is their lack of awareness of HIV-positive status and extremely limited access to treatment. These findings highlight a need for more comprehensive testing programs among PWID to increase HIV status awareness and drug resistance genotyping prior to ART initiation to ensure effective treatment of resistant HIV strains.

Acknowledgements

We thank the surveillance team for their efforts in mapping, data collection, specimen collection and data entry. We also thank the participants who took part in the surveys for their time and participation. We thank Kiana Kadivar (National Sexually Transmitted and Blood Borne Infection Laboratory) for her initial assistance with coordinating serological testing.

References

256

257 1. UNAIDs. Country Progress Report - Pakistan [Internet]. 2020 [cited 2023 Oct 29]. 258 Available from: 259 https://www.unaids.org/sites/default/files/country/documents/PAK 2020 countryreport.p 260 df 261 UNAIDs. Country Factsheets: Pakistan [Internet]. 2022 [cited 2023 Aug 13]. Available 2. 262 from: https://www.unaids.org/en/regionscountries/countries/pakistan 263 Lim AG, Trickey A, Thompson LH, Emmanuel F, Reza TE, Reynolds R, et al. 3. 264 Elucidating Drivers for Variations in the Explosive Human Immunodeficiency Virus 265 Epidemic among People Who Inject Drugs in Pakistan. Open Forum Infect Dis. 266 2021;8(9). 267 4. Salman Y, Shaeen SK, Butt MS, Vohra LI, Hashmi T. HIV in Pakistan: Challenges, 268 efforts and recommendations. Ann Med Surg. 2022:84. 269 5. Shah S, Xing H, Altaf A, Chen B, Liao L, Jia Y, et al. Antiretroviral drug resistance 270 mutations among treated and treatment-naive patients in Pakistan: Diversity of the HIV 271 type 1 pol gene in Pakistan. AIDS Res Hum Retroviruses. 2011;27(12). 272 Capelastegui F, Trickey A, Thompson LH, Reza T, Emmanuel F, Cholette F, et al. Risk 6. 273 factors of HIV and variation in access to clean needles among people who inject drugs in 274 Pakistan. Pathog Glob Health. 2023;117(8). 275 7. Nai Zindagi Trust. ART adherence unit: A therapeutic community facility that aims to 276 improve HIV treatment outcomes for people who inject drugs in Pakistan [Internet]. 2016 277 [cited 2023 Nov 2]. Available from: https://www.naizindagi.org/treatment-and-adherence/

- 8. Bergenstrom A, Achakzai B, Furqan S, ul Haq M, Khan R, Saba M. Drug-related HIV
- epidemic in Pakistan: A review of current situation and response and the way forward
- 280 beyond 2015. Harm Reduct J. 2015;12(1).
- 281 9. Malta M, Magnanini MMF, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy
- among HIV-infected drug users: A meta-analysis. AIDS Behav. 2010;14(4).
- Nosyk B, Min JE, Colley G, Lima VD, Yip B, Milloy MJS, et al. The causal effect of
- opioid substitution treatment on HAART medication refill adherence. AIDS. 2015;29(8).
- 285 11. Iversen J, Qureshi S ul H, Zafar M, Busz M, Maher L. Adherence to antiretroviral therapy
- among HIV positive men who inject drugs in Pakistan. Int J Drug Policy. 2021;96.
- 287 12. Daud MY ousuf, Qazi RA ziz, Bashir N. Anti-retroviral drugs compliance in intravenous
- and non intravenous drug abusers. J Ayub Med Coll Abbottabad. 2014;26(4).
- 289 13. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between
- Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug
- Resistance. Clin Infec Dis. 2003;37(8).
- 292 14. WHO. HIV drug resistance report 2017 [Internet]. Geneva; 2017 [cited 2023 Dec 7].
- 293 Available from: https://iris.who.int/bitstream/handle/10665/255896/9789241512831-
- 294 <u>eng.pdf</u>
- 295 15. McCluskey SM, Siedner MJ, Marconi VC. Management of Virologic Failure and HIV
- 296 Drug Resistance. Infect Dis Clin North Am. 2019;33(3).
- 297 16. van Zyl G, Bale MJ, Kearney MF. HIV evolution and diversity in ART-treated patients.
- 298 Retrovirology. 2018;15(1).
- 299 17. Ávila-Ríos S, García-Morales C, Matías-Florentino M, Romero-Mora KA, Tapia-Trejo D,
- Quiroz-Morales VS, et al. Pretreatment HIV-drug resistance in Mexico and its impact on

301 the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO 302 survey. Lancet HIV. 2016;3(12). 303 18. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. 304 HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in 305 low-income and middle-income countries: a systematic review and meta-regression 306 analysis. Lancet Infect Dis. 2018;18(3). 307 19. Hamers RL, Schuurman R, Sigaloff KCE, Wallis CL, Kityo C, Siwale M, et al. Effect of 308 pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance 309 outcomes of first-line antiretroviral treatment in sub-Saharan Africa: A multicentre cohort 310 study. Lancet Infect Dis. 2012;12(4). 311 20. Des Jarlais DC, Kerr T, Carrieri P, Feelemyer J, Arasteh K. HIV infection among persons 312 who inject drugs: Ending old epidemics and addressing new outbreaks. AIDS. 2016;30(6). 313 21. Pham QD, Wilson DP, Law MG, Kelleher AD, Zhang L. Global burden of transmitted 314 HIV drug resistance and HIV-exposure categories: A systematic review and meta-315 analysis. AIDS. 2014;28(18). 316 22. Emmanuel F, Archibald C, Razague A, Sandstrom P. Factors Associated With an 317 Explosive HIV Epidemic Among Injecting Drug Users in Sargodha, Pakistan. JAIDS. 318 2009 May;51(1):85–90. 319 23. Samo RN, Altaf A, Agha A, Pasha O, Rozi S, Memon A, et al. High HIV incidence 320 among persons who inject drugs in Pakistan: Greater risk with needle sharing and 321 injecting frequently among the homeless. PLoS One. 2013;8(12).

- 322 24. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk
- environment for injecting drug users: The past, present, and future. Lancet.
- 324 2010;376(9737).
- 325 25. Khan S, Zahid M, Qureshi MA, Mughal MN, Ujjan ID. HIV-1 genetic diversity,
- geographical linkages and antiretroviral drug resistance among individuals from Pakistan.
- 327 Arch Virol. 2018;163(1).
- 328 26. Siddiqui D, Badar U, Javaid M, Farooqui N, Shah SA, Iftikhar A, et al. Genetic and
- antiretroviral drug resistance mutations analysis of reverse transcriptase and protease gene
- from Pakistani people living with HIV-1. PLoS One. 2023;18(8 August).
- 331 27. Abidi SH, Nduva GM, Siddiqui D, Rafaqat W, Mahmood SF, Siddiqui AR, et al.
- Phylogenetic and Drug-Resistance Analysis of HIV-1 Sequences From an Extensive
- Paediatric HIV-1 Outbreak in Larkana, Pakistan. Front Microbiol. 2021;12.
- 28. Cholette F, Joy J, Pelcat Y, Thompson LH, Pilon R, Ho J, et al. HIV-1 phylodynamic
- analysis among people who inject drugs in Pakistan correlates with trends in illicit opioid
- 336 trade. PLoS One. 2020 Aug 28;15(8):e0237560.
- 29. Emmanuel F, Blanchard J, Zaheer HA, Reza T, Holte-Mckenzie M. The HIV/AIDS
- 338 Surveillance Project mapping approach: An innovative approach for mapping and size
- estimation for groups at a higher risk of HIV in Pakistan. AIDS. 2010;24(SUPPL. 2).
- 340 30. Woods CK, Brumme CJ, Liu TF, Chui CKS, Chu AL, Wynhoven B, et al. Automating
- 341 HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J
- 342 Clin Microbiol. 2012;50(6).
- 343 31. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular evolutionary
- genetics analysis across computing platforms. Mol Biol Evol. 2018;35(6).

345 32. Pineda-Peña AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al. 346 Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: 347 Performance evaluation of the new REGA version 3 and seven other tools. Infect Genet 348 Evol. 2013;19. 349 Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: Adaptive context-33. 350 based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 351 2014;42(18). 352 Pond SLK, Posada D, Stawiski E, Chappey C, Poon AFY, Hughes G, et al. An 34. 353 evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and 354 subtype prediction in HIV-1. PLoS Comput Biol. 2009;5(11). 355 35. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human 356 immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic 357 Acids Res. 2003;31(1). 358 36. Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy 359 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17(3). 360 37. WHO. WHO HIVResNet HIV drug resistance laboratory operational framework, second 361 edition. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO; 2020. 362 38. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug 363 resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. 364 PLoS One. 2009;4(3). 365 39. Bansode V, Drebert ZJ, Travers SAA, Banda E, Molesworth A, Crampin A, et al. Drug 366 resistance mutations in drug-naive HIV type 1 subtype C-infected individuals from rural

Malawi. AIDS Res Hum Retroviruses. 2011;27(4).

- 368 40. Rhee SY, Tzou PL, Shafer RW. Temporal trends in hiv-1 mutations used for the
- surveillance of transmitted drug resistance. Viruses. 2021;13(5).
- 370 41. Rhee SY, Liu TF, Holmes SP, Shafer RW. HIV-1 subtype B protease and reverse
- transcriptase amino acid covariation. PLoS Comput Biol. 2007;3(5).
- 372 42. Melikian GL, Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, et al. Standardized
- comparison of the relative impacts of HIV-1 Reverse Transcriptase (RT) mutations on
- nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother. 2012;56(5).
- 375 43. Li S, Ouyang J, Zhao B, An M, Wang L, Ding H, et al. The S68G polymorphism is a
- compensatory mutation associated with the drug resistance mutation K65R in CRF01 AE
- 377 strains. BMC Infect Dis. 2020;20(1).
- 378 44. Xu HT, Colby-Germinario SP, Huang W, Oliveira M, Han Y, Quan Y, et al. Role of the
- K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other
- nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother.
- 381 2013;57(11).
- Wang Y, Xing H, Liao L, Wang Z, Su B, Zhao Q, et al. The development of drug
- resistance mutations K103N Y181C and G190A in long term Nevirapine-containing
- antiviral therapy. AIDS Res Ther. 2014;11(1).
- 385 46. Chin BS, Shin HS, Kim G, Wagner GA, Gianella S, Smith DM. Short communication:
- Increase of HIV-1 K103N transmitted drug resistance and its association with Efavirenz
- use in South Korea. AIDS Res Hum Retroviruses. 2015;31(6).
- 388 47. Yan L, Yu F, Zhang H, Zhao H, Wang L, Liang Z, et al. Transmitted and acquired hiv-1
- drug resistance from a family: A case study. Infect Drug Resist. 2020;13.

390 48. Kuznetsova A, Lebedev A, Gromov K, Kazennova E, Zazzi M, Incardona F, et al. 391 Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the 392 efficacy of first-line antiretroviral therapy regimens using rilpivirine in human 393 immunodeficiency virus-infected patients. Clin Case Rep. 2022;10(2). 394 49. Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, et 395 al. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their 396 interactions with the M184I mutation on defining patterns of resistance to nonnucleoside 397 reverse transcriptase inhibitors rilpivirine and etravirine. Antimicrob Agents Chemother. 398 2013;57(7). 399 50. Liu Y, Zhang Y, Li H, Wang X, Jia L, Han J, et al. Natural presence of the V179D and 400 K103R/V179D mutations associated with resistance to nonnucleoside reverse 401 transcriptase inhibitors in HIV-1 CRF65 cpx strains. BMC Infect Dis. 2020;20(1). 402 51. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, et al. Resistance 403 profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from 404 the randomized, controlled Phase III clinical studies. AIDS. 2010;24(4). 405 52. Stanford University HIV Drug Resistance Database. NNRTI Resistance Notes [Internet]. 406 2022 [cited 2023 Sep 4]. Available from: https://hivdb.stanford.edu/dr-407 summary/resistance-notes/NNRTI/ 408 Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, De Oliveira T, et al. 53. 409 Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on 410 susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents 411 Chemother. 2015;59(2).

NACP. Consolidation Guidelines for the Prevention and Treatment of HIV and AIDS in 412 54. 413 Pakistan [Internet]. 2020 [cited 2024 Jan 9]. Available from: 414 https://nacp.gov.pk/howwework/technicalguidelinestac.html 415 55. NACP. Consolidated Guidelines for the Treatment of HIV and AIDS in Pakistan 416 [Internet]. 2015 [cited 2024 Jan 9]. Available from: 417 https://nacp.gov.pk/howwework/technicalguidelinestac.html 418 56. Mohan A, Shaikh MTA, Wara UU, Rackimuthu S, Costa AC dos S, Lal PM, et al. 419 HIV/AIDS among children in Ratodero, Pakistan amidst the COVID-19 pandemic: 420 Challenges, efforts, and recommendations. Clin Epidemiol Glob Health. 2021;12. 421 57. WHO. Who. 2019 [cited 2024 Jan 10]. Update of recommendations on first- and second-422 line antiretroviral regimens. Available from: 423 https://www.who.int/publications/i/item/WHO-CDS-HIV-19.15 424 58. Emmanuel F, Fatima M. Coverage to curb the emerging HIV epidemic among injecting 425 drug users in Pakistan: Delivering prevention services where most needed. Int J Drug 426 Policy. 2008;19(SUPPL. 1). 427 59. Archibald CP, Shaw SY, Emmanuel F, Otho S, Reza T, Altaf A, et al. Geographical and 428 temporal variation of injection drug users in Pakistan. Sex Transm Infect. 429 2013;89(SUPPL. 2). 430 60. Emmanuel F, Salim M, Akhtar N, Arshad S, Reza TE. Second-generation surveillance for 431 HIV/AIDS in Pakistan: results from the 4th round of Integrated Behavior and Biological 432 Survey 2011–2012. Sex Transm Infect. 2013 Nov;89(Suppl 3):iii23–8.

Khan AA, Awan AB, Qureshi SU, Razaque A, Zafar ST. Large sharing networks and unusual injection practices explain the rapid rise in HIV among IDUs in Sargodha,
Pakistan. Harm Reduct J. 2009;6.
UNAIDs. UNAIDS DATA 2020 [Internet]. 2020 [cited 2023 Dec 11]. Available from:
https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf